Skip to content
Home/Companies/Biotech/NovaSAID

NovaSAID

Biotech·Sweden·Active·13yr hold
Entry
2013
Hold
13yr
Status
Active

Who owns NovaSAID?

NovaSAID is a Swedish Biotech company, currently owned by Rosetta Capital since 2013.

Hand-verified · updated 2026-06-30

Open JSON · CC-BY
Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorBiotech
StatusActive

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Akinion Pharmaceuticals
Active
PharmaSweden· 2013
Aprea Therapeutics
Exited 2019
BiotechSweden· 2013
Axelar
Active
BiotechSweden· 2013
Biosergen
Exited 2021
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Dilafor
Active
BiotechSweden· 2013

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns NovaSAID?

NovaSAID is currently owned by Rosetta Capital, through Rosetta Capital IV, since 2013.

When did Rosetta Capital acquire NovaSAID?

Rosetta Capital acquired NovaSAID in 2013.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue